|Articles|April 14, 2021
- Pharmaceutical Executive-04-01-2021
- Volume 41
- Issue 4
Pharmaceutical Executive, April 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternativealmost 5 years ago
The Challenges of Worker Qualification Management in Pharmaalmost 5 years ago
The Future of Telehealth: Evolving COVID Perspectives Offer Cluesalmost 5 years ago
Years in the Making: A Repeat Recognition—Uninterruptedalmost 5 years ago
Pharm Exec at 40 (1990-1993)almost 5 years ago
The Power of Parityalmost 5 years ago
No Limits to Science, Or Selfalmost 5 years ago
In Silico in Sight as Biopharma Game-Changeralmost 5 years ago
Long-View Innovation Hopes for Pharma Policy in the EUNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success
2
Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage
3
JP Morgan 2026: AbbVie Advances its Pipeline
4
JP Morgan 2026: Genmab Prioritizing Sustained Growth Over Next Decade
5

